IPM Take
Healthcare systems have traditionally treated obesity, diabetes, chronic kidney disease and cardiovascular disease as separate clinical problems managed by different specialists. The new CKM syndrome guideline challenges that model. By formally recognising these conditions as interconnected manifestations of a single disease process, the guideline shifts the conversation from treating complications to preventing them. The biggest challenge may not be adopting new medicines or risk calculators, but redesigning healthcare systems that remain organised around clinical silos rather than patient journeys.
Executive Summary
The American Heart Association, American College of Cardiology, American Diabetes Association and American Society of Nephrology have jointly released the first-ever guideline on cardiovascular-kidney-metabolic (CKM) syndrome. The document introduces a unified framework linking obesity, type 2 diabetes, chronic kidney disease and cardiovascular disease and outlines recommendations for prevention, screening, risk assessment and treatment. Key recommendations include earlier intervention, use of the PREVENT cardiovascular risk equations, routine assessment of kidney function, greater attention to social determinants of health and wider adoption of therapies such as GLP-1 receptor agonists and SGLT2 inhibitors. The guideline also calls for coordinated multidisciplinary care models to address the growing burden of cardiometabolic disease.
Why it matters
- Policymakers: The guideline strengthens the case for integrated prevention strategies that cut across traditional disease programmes.
- Health systems: Coordinated care models may become increasingly important as patients present with multiple interconnected chronic conditions.
- Payers: Earlier intervention may increase short-term spending but could reduce costly cardiovascular and kidney complications over time.
- Clinicians: Risk assessment now extends beyond cardiovascular factors alone to include kidney and metabolic health.
- Patients: Earlier identification and intervention may help prevent progression to advanced cardiovascular and kidney disease.
For years, healthcare systems have approached obesity, diabetes, kidney disease and cardiovascular disease as distinct conditions.
Patients often move between specialists, clinics and treatment pathways that operate independently from one another. Cardiologists manage cardiovascular risk. Endocrinologists focus on diabetes. Nephrologists oversee kidney disease. Weight management frequently exists in yet another silo.
The new cardiovascular-kidney-metabolic (CKM) syndrome guideline argues that this model no longer reflects biological reality.
Developed jointly by the American Heart Association, American College of Cardiology, American Diabetes Association and American Society of Nephrology, the guideline presents obesity, type 2 diabetes, chronic kidney disease and cardiovascular disease as interconnected manifestations of a shared disease process. Rather than focusing primarily on end-stage complications, the document emphasises identifying risk earlier and intervening before irreversible organ damage occurs.
The implications extend well beyond clinical practice.
One of the most notable recommendations is the adoption of a staged approach to CKM syndrome that encourages intervention long before cardiovascular events develop. The guideline also supports the use of newer PREVENT risk equations, which incorporate metabolic and kidney health measures to provide a more comprehensive assessment of long-term cardiovascular risk.
The document further highlights the growing role of therapies that act across multiple organ systems. GLP-1-based medicines, SGLT2 inhibitors and kidney-protective therapies are increasingly being positioned not as treatments for individual diseases but as tools for modifying interconnected cardiometabolic risk.
Equally significant is the guideline’s focus on care delivery.
The authors call for coordinated interdisciplinary care and recommend the use of dedicated CKM coordinators or navigators to support patients across different specialties. This reflects growing recognition that fragmented care pathways often fail patients living with multiple chronic conditions.
The guideline also highlights social drivers of health, including housing instability, food insecurity and financial strain, as factors that should be routinely assessed as part of CKM care. This signals a broader shift toward prevention models that recognise the role of social and environmental factors in disease progression.
For personalised medicine, the document represents another step away from one-size-fits-all prevention.
Risk prediction is becoming increasingly individualised, integrating metabolic, cardiovascular and renal factors into a more comprehensive understanding of future disease risk. The objective is not simply identifying who is sick today, but who is most likely to become sick tomorrow.
The real test, however, will be implementation.
The guideline authors acknowledge that many healthcare systems remain organised around separate specialties, fragmented reimbursement structures and disconnected care pathways. Successfully implementing the CKM framework may require changes to workforce training, reimbursement models, care coordination mechanisms and digital infrastructure.
In that sense, the guideline is about more than cardiometabolic disease.
It represents an attempt to redesign healthcare around interconnected risk rather than isolated diagnoses. Whether health systems are ready for that shift remains an open question.
